Moody Aldrich Partners LLC Blueprint Medicines Corp Transaction History

Moody Aldrich Partners LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 23, 2023	SELL	$41.06 - $66.48 $28,618 - $46,336	-697 Reduced 3.83%	17,489 $0
Q3 2022 Oct 18, 2022	BUY	$49.93 - $77.7 $908,026 - $1.41 Million	18,186 New	18,186 $1.2 Million
Q1 2020 May 07, 2020	SELL	$48.11 - $82.22 $891,093 - $1.52 Million	-18,522 Closed	0 $0
Q4 2019 Feb 07, 2020	SELL	$66.73 - $82.59 $49,113 - $60,786	-736 Reduced 3.82%	18,522 $1.48 Million
Q3 2019 Nov 12, 2019	BUY	$72.9 - $101.41 $1.4 Million - $1.95 Million	19,258 New	19,258 $1.42 Million

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Moody Aldrich Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Moody Aldrich Partners LLC with notifications on news.